REFERENCES
- Holmberg H, Carlsson P. Kalman D, Varenhorst E. Impact on health service costs of medical technologies used in management of prostatic cancer. Scand J Urol Nephrol 1998; 32: 195–9.
- Lampic C, Wennberg A, Schill J-E, Brodin O, Glimelius B, SjOden P-O. Anxiety and cancer-related worry of cancer patients at routine follow-up visits. Acta Oncol 1994; 33: 119–25.
- Lampic C, Wennberg A, Schill J-E, Glimelius B, Brodin O, SjOden P-O. Coping, psychosocial well-being and anxiety in cancer patients at follow-up visits. Acta Oncol 1994; 33: 887–94.
- Carroll BT, Kathol RG, Noyes Jr R, Wald TG, Clamon GH. Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry 1993; 15: 69–74.
- Snee M. Follow-up of women treated for breast cancer. Clin Oncol 1996; 8: 85–9.
- Kjeldsen KJ, Kronborg O, Fenger C, Jorgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 1997; 84: 666–9.
- Oh J, Colberg J, Ornstein D, Johnson E, Chan D, Virgo K, et al. Current follow-up strategies after radical prostatectomy: a survey of American Urological Asso-ciation urologists. J Urol 1999; 161: 520–3.
- James N, Guerrero D, Brada M. Who should follow up cancer patients? Nurse specialist based outpatient care and the introduction of a phone clinic system. Clin Oncol 1994; 6: 283–7.
- Mayled A. Medical admissions units: the role of the nurse practitioner. Nurs Stand 1998; 12: 44–7.
- Wiles R. Empowering practice nurses in the follow-up of patients with established heart disease: lessons from patients' experiences. J Adv Nurs 1997; 26: 729–35.
- Timpka T, Svensson B, Molin B. Development of community nursing: analysis of the central services and practice dilemmas. Int J Nurs Stud 1996; 33: 297–308.
- Leung HY, Davis M, Arnold D, Hamdy FC, Neal DE. The role of the nurse practitioner in a urology service. Br J Urol 1996; 77: 502–5.
- Murphy PA, Fullerton J. Outcomes of intended home births in nurse-midwifery practice: a prospective descriptive study. Obstet Gynecol 1998; 92: 461–70.
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–70.
- Spinhoven P. Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 1997; 27: 363–70.
- Herrmann C. International experiences with the Hospital Anxiety and Depression Scale-a review of validation data and clinical results. J Psychosom Res 1997; 42: 17–
- Ibbotson T, Maguire P. Selby P. Priestman T, Wallace L. Screening for anxiety and depression in cancer
- UICC. Union Internationale contre le Cancer. TNM Classification of Malignant Tumours. 3rd ed. Geneva: International Union Against Cancer, 1987.
- Edelman M, Meyers F, Siegel D. The utility of follow-up testing after curative cancer therapy. J Gen Intern Med 1997; 12: 318�31.
- Adolfsson J, Steineck G, Hedlund P-O. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up
- Johansson J-E, Holmberg L, Johansson S, Bergstrom R, Adami H-O. Fifteen-year survival in prostate cancer. A
- Rana A, Chrisholm M, Khan M, Rashwan H, Elton R. Conservative management with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate. Br J Urol 1994; 74: 637–41.
- Mazeman E, Bertrand P. Early versus delayed hormonal therapy in advanced prostate cancer. Eur Urol 1996; 30(Suppl 1): 40–3.
- Byar DP. Proceedings: the Veterans' Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126–30.
- Lepor H, Ross A, Walsh P. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982; 128: 335–40.
- The Medical Research Council Prostate Cancer Working Party Investigators Group.. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235–46.
- Kramolowsky E. The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 1988; 139: 1242–4.
- Herr H, Kornblith A, Ofman U. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993; 71: 1143–50.